地他唑对大鼠实验性糖尿病视网膜血管形态的影响。

Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats.

作者信息

Moreno A, De La Cruz J P, Mérida F, García Campos J, Sánchez de la Cuesta F

机构信息

Department of Ophthalmology, School of Medicine, University of Málaga, Spain.

出版信息

Haemostasis. 1995 Jul-Aug;25(4):166-71. doi: 10.1159/000217157.

DOI:10.1159/000217157

PMID:7557655

Abstract

Platelets from diabetic patients are hypersensitive to aggregating agents. An imbalance in thromboxane/prostacyclin synthesis has been postulated as an antecedent to the development of diabetic retinopathy. We studied 3-month streptozotocin-diabetic rats (SDR) treated with 200 mg/kg/day p.o. of ditazol, an antiplatelet drug that inhibits thromoboxane formation. Thromboxane B2 (TxB2) production was higher and 6-keto-PGF1 alpha synthesis lower in SDR than nondiabetic rats (NDR). In treated animals, ditazol inhibited platelet aggregation by 66%, and TxB2 production by 58%, and increased vascular 6-keto-PGF 1 alpha by 45%. Furthermore, 13% of the retinal surface was covered by peroxidase-labelled vessels in NDR, 2.1% in nontreated SDR, and 8.9% in SDR treated with ditazol. We postulate that ditazol may prevent or reduce diabetic retinopathy.

摘要

糖尿病患者的血小板对聚集剂高度敏感。血栓素/前列环素合成失衡被认为是糖尿病视网膜病变发生的先兆。我们研究了用200毫克/千克/天口服双嘧达莫（一种抑制血栓素形成的抗血小板药物）治疗3个月的链脲佐菌素诱导的糖尿病大鼠（SDR）。与非糖尿病大鼠（NDR）相比，SDR中血栓素B2（TxB2）的产生更高，而6-酮-前列环素F1α的合成更低。在接受治疗的动物中，双嘧达莫抑制血小板聚集66%，抑制TxB2产生58%，并使血管6-酮-前列环素F1α增加45%。此外，NDR中13%的视网膜表面被过氧化物酶标记的血管覆盖，未治疗的SDR中为2.1%，用双嘧达莫治疗的SDR中为8.9%。我们推测双嘧达莫可能预防或减轻糖尿病视网膜病变。